ARS Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue reached $22.7M, driven by strong neffy adoption and expanded access. Key initiatives to reduce prescribing friction and improve affordability are expected to accelerate growth, with CVS Caremark approval and back-to-school season poised to boost demand.
-
Key goals include expanding neffy access to 90% coverage and advancing urticaria clinical trials, with strong pediatric uptake and high prescriber confidence. International launches, especially in Europe and China, are progressing well, and refill dynamics are expected to drive future growth.
Fiscal Year 2025
-
2025 saw $84.3M in revenue and strong neffy adoption, with 93% commercial coverage and expanding DTC awareness. Sales force expansion and disciplined SG&A will support growth, while refill dynamics and broader access are expected to drive momentum in 2026.
-
Neffy adoption is accelerating, with over 20,000 prescribers and strong real-world data supporting its use. Access is expanding through payer coverage and the Get Neffy on Us program, while international launches are achieving premium pricing. Pipeline progress includes a lower-dose formulation for CSU.
-
Q3 2025 saw U.S. neffy revenue surge 2.5x to $31.3M, exceeding expectations, with strong new patient growth and high refill intent. Strategic DTC campaigns and the Get neffy on Us program are driving adoption, while international launches and robust cash reserves support long-term growth.
-
Neffy’s launch is progressing with increased physician adoption and a robust DTC campaign driving awareness and preference, especially among pediatric patients. Market share is expected to grow through improved access, competitive pricing, and upcoming formulary wins, while legislative efforts and real-world data further support adoption.
-
Q2 2025 saw $12.8M in U.S. net product revenue for neffy, up 64% from Q1, with 93% commercial coverage and accelerating prescription growth. International expansion and a robust DTC campaign are expected to drive further gains, supported by a strong cash position.
-
neffy, a needle-free epinephrine, is rapidly gaining market share with strong physician adoption, broad payer coverage, and a major DTC campaign. International launches and a new urticaria indication could further expand its multi-billion dollar market potential.
-
neffy, a needle-free epinephrine nasal spray, is gaining rapid adoption with strong sales, broad insurance coverage, and expanding global approvals. Strategic DTC campaigns and partnerships are driving awareness, while robust IP and a growing pipeline support long-term growth.
-
Q1 2025 saw $7.8M in Neffy revenue, 57% insurance coverage, and the launch of a pediatric dose. A major DTC campaign and expanded ALK partnership aim to drive growth, with an inflection in sales expected in Q3 as coverage and awareness increase.
-
Neffy, a needle-free intranasal epinephrine spray, has seen strong early sales and rapid adoption, driven by pent-up demand, physician comfort, and improving insurance coverage. Pediatric use is high, and a direct-to-consumer campaign is set to further boost awareness and uptake.
-
neffy, a needle-free epinephrine product, is rapidly gaining market share with strong physician adoption, broadening insurance coverage, and robust global partnerships. Strategic marketing, school outreach, and new clinical indications are set to drive further growth.
Fiscal Year 2024
-
Neffy’s U.S. launch drove $7.3M in 2024 sales, with rapid payer coverage expansion and strong physician adoption. 80% unrestricted commercial access is expected by summer 2025, supported by a robust cash position and major DTC campaign.
-
neffy, a needle-free nasal epinephrine spray, is seeing strong early U.S. uptake, targeting both dissatisfied current users and new patients, with exclusivity until 2038 and robust payer and physician engagement. Commercial coverage and consumer marketing are set to expand, supporting a multi-billion-dollar market opportunity.
-
Neffy, a needle-free nasal epinephrine, is seeing strong early adoption and payer support, with a focus on converting and expanding the allergy market. The product offers clinical, practical, and economic advantages, and a lower-dose version is in development for CSU flares.
-
neffy, the first needle-free epinephrine, launched in the US and Europe with strong early adoption and positive feedback from patients and providers. Q3 revenue reached $2.1M, with a $145M cash infusion from a licensing deal supporting global expansion and accelerated launch plans.
-
FDA approved neffy, the first needle-free epinephrine nasal spray for allergic reactions, offering a safe, easy-to-use alternative to auto-injectors. Clinical data show comparable efficacy and safety to injections, with a 30-month shelf life and robust stability. Launch is expected within 8 weeks, supported by broad education and access programs.